FORT WORTH, Texas, July 7 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (WNDM.ob), announced today that it will exhibit at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing (NCVH) conference in New Orleans July 9-11.
NCVH has become the largest multidisciplinary conference in the country, bringing together cardiologists, surgeons, podiatrists, wound care specialists, family practice physicians, diabetologists, and many other clinicians and specialists who are involved in all aspects of limb salvage, podiatric wound care, and peripheral vascular treatment. There are over 1,000 expected attendees and one of the most distinguished faculty lists in the industry.
Two peer reviewed abstracts being presented at the conference featuring Wound Care Innovations’ advanced wound care collagen product, CellerateRx(R). One of the abstracts is entitled “Emerging Use of Topical Biologics in Limb Salvage: The Role of ‘Activated Collagen’ in the multimodality Treatment” presented by Gary M. Rothenberg, DPM, Director of Resident Training-Attending Podiatrist, Miami VA Healthcare System. Dr. Rothenberg is also one of the featured speakers and will be presenting “Prophylactic Surgery in the Diabetic Foot and Partial Ray Amputation Outcomes.”
Also being presented is “CellerateRx(R) An Evidence Based Skin Tear Study: Interim Evaluation” by Dr. Jane Fore, MD, FAPWCA, FACCWS, Medical Director, Tri-State Wound Care and Hyperbaric Center. In addition, Dr. Fore will be conducting a series of workshops on “The Benefits of Collagen in Wound Healing: Methods of Action and Selection of Collagen Containing Dressings.”
“I am delighted to be conducting the workshop on collagen dressings,” states Dr. Fore. “I have been using CellerateRx(R) in my wound care protocols for over 5 years now and it is an essential part of my wound care treatments for success. I am excited to be able to show practitioners the many ways CellerateRx(R) can be used in their wound care practice, especially with difficult or challenging wounds such as diabetic ulcers.”
“We are particularly excited about exhibiting at the NCVH conference this year,” states Cathy Bradshaw, President of Wound Care Innovations. “It allows us to be with the industry leaders and promote our advanced wound care product, CellerateRx(R). In addition, the two abstracts and workshop provides an excellent opportunity to highlight the many unique features and characteristics of CellerateRx(R), particularly in diabetic wound care. Diabetic ulcers are one of the largest challenges in the health care industry today, both for the patient and economic expenditures. Statistics show that around 85% of Lower Extremity Amputation’s begin with an ulcer; therefore a product that manages these wounds more effectively can save limbs and resources. We are especially seeing great results with the use of CellerateRx(R) on diabetic ulcers and data continues to support this. We fully expect that these results will help us to increase our market share in the U.S. and generate sales internationally.”
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. , with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company’s Website at www.Celleraterx.com .
“Safe Harbor” Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
CONTACT: Product Information: Cathy Bradshaw, President, +1-954-315-9242,
or Shareholder Relations, Lucy Singleton, Secretary, +1-817-820-7080
Web site: http://www.Celleraterx.com/
